Advertisement
Australia markets close in 1 hour 31 minutes
  • ALL ORDS

    7,805.10
    -93.80 (-1.19%)
     
  • ASX 200

    7,554.60
    -87.50 (-1.14%)
     
  • AUD/USD

    0.6402
    -0.0024 (-0.37%)
     
  • OIL

    84.64
    +1.91 (+2.31%)
     
  • GOLD

    2,402.30
    +4.30 (+0.18%)
     
  • Bitcoin AUD

    97,868.52
    +1,104.69 (+1.14%)
     
  • CMC Crypto 200

    1,286.05
    +400.51 (+43.97%)
     
  • AUD/EUR

    0.6015
    -0.0016 (-0.26%)
     
  • AUD/NZD

    1.0879
    +0.0004 (+0.03%)
     
  • NZX 50

    11,762.94
    -73.10 (-0.62%)
     
  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     
  • FTSE

    7,877.05
    +29.06 (+0.37%)
     
  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     
  • DAX

    17,837.40
    +67.38 (+0.38%)
     
  • Hang Seng

    16,184.02
    -201.85 (-1.23%)
     
  • NIKKEI 225

    37,161.01
    -918.69 (-2.41%)
     

Femasys Inc. to Present at The MedTech Conference

ATLANTA, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that Kathy Lee-Sepsick, chairman, president and chief executive officer, will participate in a presentation at The MedTech Conference. Ms. Lee-Sepsick will speak on a panel in a session, entitled, “Early-Stage Medtech and Going Public.” The MedTech Conference, an annual event powered by AdvaMed, convenes the world’s leaders in medical technology and will be held on a hybrid basis from September 21st-30th this year.

Below is the session information for “Early-Stage Medtech and Going Public”:

Date and Time: Thursday, September 30 at 10:00 a.m. – 10:35 a.m. ET

Location: Hyatt Regency Minneapolis, Great Lakes Ballroom, 1300 Nicollet Mall, Minneapolis, MN 55403

About Femasys
Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc® permanent birth control and FemaSeedlocalized directional insemination for infertility. The Company’s product for fallopian tube assessment by ultrasound, FemVue®, is currently marketed in the United States. Femasys is also advancing FemCerv®, a technology platform for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.

ADVERTISEMENT

Contacts:

Investors

Chuck Padala
LifeSci Advisors, LLC
+1-917-741-7792
chuck@lifesciadvisors.com

Media
Sky Striar
LifeSci Communications
sstriar@lifescicomms.com

Femasys Inc.

Investor Contact:
IR@femasys.com

Media Contact:
Media@femasys.com